Any current/future new fundraising through debt or equity?

As of now, Entero Healthcare Solutions Limited does not have any immediate plans for new fundraising through debt or equity. The company has unutilized proceeds from its IPO and significant cash on its balance sheet, which it intends to use for future acquisitions. Positive operating cash flows expected in the near future will further support acquisitions without the need for additional fundraising. External capital will primarily be used for inorganic growth, leveraging IPO proceeds already raised. Management has confirmed no immediate fundraising plans and prefers to utilize internal accrual

Any current/future capex/capital investment/strategic investment?

No explicit mention of current or future capex or capital investment plans in the transcript. Focus remains on inorganic growth through acquisitions; recently completed 10 acquisitions and pipeline continues. Investments largely in acquisitions to expand geographic footprint, product portfolio, and capabilities. Emphasis on operational efficiencies, technology-led solutions, and building a digitally integrated healthcare distribution platform. Working capital improvements and margin expansion targeted to drive positive operating cash flows from FY ‘26. No indication of large capex or strategic

Future growth expectations in sales/revenue/volumes?

Targeting over 30% revenue growth in FY ‘26, similar or better than FY ‘25’s 30% growth. FY ‘25 growth comprised 16% organic growth and remaining from acquisitions; organic growth is expected to continue at 1.5x to 2x the Indian Pharmaceutical Market (IPM) growth rate. IPM assumed growth is ~8%; therefore, organic growth is anticipated around 15%-16%. Full-year impact of last year’s acquisitions expected to add approximately Rs. 500 crores. New acquisitions in FY ‘26 expected to add over Rs. 400 crores in annualized revenues. Long-term plan includes doubling down on organic expansion via new p

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention a current or expected order book or pending orders. Discussion focuses on acquisitions, integration timelines, and revenue growth guidance. Prabhat Agarwal mentions a timeline of about two to two and a half months to close remaining acquisitions, aiming to complete sooner. Total consideration for acquisitions is confidential; multiples are guided between 5x to 7x EV/EBITDA. The company expects 30% revenue growth for FY '26 driven by organic growth and acquisitions. No direct reference to order book or pending orders was made in the transcript on page

IN US

Sale is live|00:00:00left today

Entero Healthcare Solutions LtdQ1 FY25Retailing

Entero Healthcare Solutions Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,162P/E: 44.6Market Cap: ₹5.2K CrSector: Retailing

Management growth scorecard

Revenue

Category 2

Margin

Category 2

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

→Targeting over 30% revenue growth in FY ‘26, similar or better than FY ‘25’s 30% growth.
→FY ‘25 growth comprised 16% organic growth and remaining from acquisitions; organic growth is expected to continue at 1.5x to 2x the Indian Pharmaceutical Market (IPM) growth rate.
→IPM assumed growth is ~8%; therefore, organic growth is anticipated around 15%-16%.
→Full-year impact of last year’s acquisitions expected to add approximately Rs. 500 crores.
→New acquisitions in FY ‘26 expected to add over Rs. 400 crores in annualized revenues.
→Long-term plan includes doubling down on organic expansion via new pharmacies, hospitals, and increased wallet share.
→Growth strategy balanced between organic growth and margin-accretive inorganic acquisitions.
→Anticipated shift towards organized distribution and digital integration to fuel expansion.
→Expectations on sustained growth driven by geographically diversified operations and expanding product portfolio including specialty pharma, medical devices, and consumables.

Margin guidance

Category 2

- FY ‘26 revenue growth target: >30%, continuing the momentum from FY ‘25 (30% growth). - Organic growth expected at 1.5x to 2x of IPM growth rate; IPM industry growth estimated at 8-10%. - EBITDA margins targeted to exceed 4% on a full-year basis in FY ‘26, with medium-term aim of around 5% or slightly higher. - Positive operating cash flow anticipated in FY ‘26, driven by margin expansion and better working capital management (targeting 60-day working capital cycle). - Longer-term margin guidance withheld; management may share FY ‘27 guidance later. - Acquisitions are margin accretive and expected to add to profitability; inorganic growth planned but to normalize in 2 years. - Profit after tax grew 2.7x in FY ‘25, signaling robust operating leverage and financial execution improvements. Overall, Entero Healthcare aims double-digit organic growth, improving EBITDA margins to 4%+ in FY ‘26, and sustained profitability growth via acquisitions and operational efficiencies.

3 more insights locked — sign up free to unlock

Fundraise plans

→As of now, Entero Healthcare Solutions Limited does not have any immediate plans for new fundraising through debt or equity.
→The company has unutilized proceeds from its IPO and significant cash on its balance sheet, which it intends to use for future acquisitions.
→Positive operating cash flows expected in the near future will further support acquisitions without the need for additional fundraising.
→External capital will primarily be used for inorganic growth, leveraging IPO proceeds already raised.
→Management has confirmed no immediate fundraising plans and prefers to utilize internal accruals and existing cash resources.

Order book

→The transcript does not explicitly mention a current or expected order book or pending orders.
→Discussion focuses on acquisitions, integration timelines, and revenue growth guidance.
→Prabhat Agarwal mentions a timeline of about two to two and a half months to close remaining acquisitions, aiming to complete sooner.
→Total consideration for acquisitions is confidential; multiples are guided between 5x to 7x EV/EBITDA.
→The company expects 30% revenue growth for FY '26 driven by organic growth and acquisitions.
→No direct reference to order book or pending orders was made in the transcript on page 21 or surrounding pages.

Capex plans

Yes

→No explicit mention of current or future capex or capital investment plans in the transcript.
→Focus remains on inorganic growth through acquisitions; recently completed 10 acquisitions and pipeline continues.
→Investments largely in acquisitions to expand geographic footprint, product portfolio, and capabilities.
→Emphasis on operational efficiencies, technology-led solutions, and building a digitally integrated healthcare distribution platform.
→Working capital improvements and margin expansion targeted to drive positive operating cash flows from FY ‘26.
→No indication of large capex or strategic investments beyond acquisition-related spends.
→Available IPO proceeds and positive operating cash flows expected to fund acquisitions without need for fresh fundraise as of now.

How does Entero Healthcare Solutions Ltd rank vs peers in Retailing?

Pro feature

1Entero Healthcare Solutions Ltd

Rev 2Mar 2

See full Retailing sector rankings

Want more stocks like Entero Healthcare Solutions Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio